Finerenone · Kerendia

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure, Chronic Kidney Disease (label: heart failure with LVEF 40% or more (HFpEF and HFmrEF))

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

track record: Reliable signal

Also approved (3)
CA
  • Chronic Kidney Disease and Type 2 Diabetes KERENDIA (finerenone) is indicated as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of: • End-stage kidney disease and a sustained decrease in estimated glomerular filtration rate, • Cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure. Heart Failure KERENDIA (finerenone) is indicated as an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) ≥40% to reduce the risk of...
Product first approved 2022Health Canada
JP
  • Treatment of chronic kidney disease associated with type 2 diabetes mellitus (excluding patients who have end-stage renal failure or are undergoing dialysis)
Product first approved 2022PMDA
EU
  • Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. For study results with respect to renal and cardiovascular events, see section 5.1. Kerendia is indicated for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in adults.
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (22)
Chronic Kidney Disease
NCT06058585 · The George Institute
2024-09-04 – 2029-12-31 · Chronic Kidney Diseases
What this study did
NCT07181135 · University Medical Center Groningen
2026-03-13 – 2027-12-31 · Chronic Kidney Disease
What this study did
NCT07598864 · Chittagong Medical College
2026-05-01 – 2027-05-01 · Diabetic Nephropathy
What this study did
NCT06580288 · Zhejiang University
2024-10-08 – 2026-10-08 · IgA Nephropathy
What this study did
NCT02545049 · Bayer
2015-09-17 – 2021-02-02 · Diabetic Kidney Disease
What this study did
Heart Failure
NCT07192952 · Bayer
2026-06-01 – 2030-12-30 · Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
What this study did
NCT07270367 · Subodh Verma
2025-12 – 2030-12 · Heart Failure
What this study did
NCT07575672 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-10-09 – 2029-12-31 · HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
What this study did
NCT06082063 · Steno Diabetes Center Copenhagen
2024-07-01 – 2029-07-01 · Cardiovascular Diseases, Heart Failure, Type 1 Diabetes, Kidney Failure
What this study did
NCT06008197 · Colorado Prevention Center
2024-01-17 – 2027-12 · Heart Failure, Acute Heart Failure
What this study did
NCT06024746 · Colorado Prevention Center
2024-07-09 – 2027-11 · Heart Failure
What this study did
Other / comorbidity
NCT07356388 · kewen Chen,MD
2025-01-30 – 2028-03-31 · Kidney Transplantation Recipients, Proteinuria Patients
What this study did
NCT06244758 · University of Erlangen-Nürnberg Medical School
2024-01-18 – 2025-11-25 · Type2diabetes
What this study did
Phase 2 (15)
Chronic Kidney Disease
NCT07594145 · Oregon Health and Science University
2026-11-01 – 2031-12-31 · Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
What this study did
NCT07819227 · University Medical Center Groningen
2025-02-11 – 2026-08-31 · Chronic Kidney Disease
What this study did
NCT06818305 · Jinling Hospital, China
2025-01-01 – 2025-10-01 · Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Nephrectomy, Chronic Kidney Disease(CKD)
What this study did
NCT01345656 · Bayer
2011-05-09 – 2012-07-16 · Heart Failure
What this study did
Other / comorbidity
NCT07815509 · The University of Hong Kong-Shenzhen Hospital
2026-09-15 – 2028-09 · Premature Ovarian Insufficiency
What this study did
NCT07799519 · National Cheng-Kung University Hospital
2026-06-09 – 2028-08-31 · Atrial Fibrillation (AF)
What this study did
NCT06906081 · Peter Rossing
2025-05-02 – 2028-01 · Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic Neuropathies
What this study did
NCT06059664 · University of North Carolina, Chapel Hill
2024-04-23 – 2027-12-31 · Kidney Transplant; Complications
What this study did
NCT06835322 · Alexandria University
2025-04-01 – 2026-04-01 · Glomerulonephritis
What this study did
Phase 1 (7)
Chronic Kidney Disease
Heart Failure
NCT07116512 · Bayer
2023-05-02 – 2023-07-28 · Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent, Healthy Volunteers
What this study did
NCT01687920 · Bayer
2012-09-17 – 2013-03-21 · Heart Failure
What this study did
Other / comorbidity
NCT02956109 · Bayer
2016-11-16 – 2017-03-17 · Pharmacokinetics
What this study did
NCT02957396 · Bayer
2016-11-17 – 2017-03-01 · Pharmacokinetics
What this study did
NCT01473108 · Bayer
2010-03-29 – 2011-05-17 · Clinical Pharmacology
What this study did
Phase 4 (26)
Chronic Kidney Disease
NCT07442448 · Cathay General Hospital
2026-04 – 2029-12 · Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction
What this study did
NCT07775846 · Huijie Zhang
2026-11-03 – 2029-06-30 · Type 2 Diabetic Kidney Disease
What this study did
NCT07547878 · Baylor Research Institute
2026-04-08 – 2029-03-31 · Chronic Kidney Disease, Type 2 Diabetes
What this study did
NCT07239570 · Peter Rossing
2025-06-20 – 2028-06 · Chronic Kidney Disease(CKD)
What this study did
NCT07026539 · University of Aarhus
2024-10-23 – 2028-04-30 · Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases
What this study did
NCT07667517 · First Affiliated Hospital of Zhejiang University
2026-07-01 – 2027-12-31 · Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
What this study did
NCT07155694 · Washington D.C. Veterans Affairs Medical Center
2026-10-01 – 2027-08 · Diabetic Kidney Disease
What this study did
NCT07537088 · First Affiliated Hospital of Wannan Medical College
2026-05 – 2027-07 · T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
What this study did
NCT06954090 · Steno Diabetes Center Copenhagen
2025-11-20 – 2027-05-31 · Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
What this study did
NCT07235891 · Alexandria University
2025-11-20 – 2027-03-20 · Retinal Nerve Fiber Layer Thickness, Chronic Kidney Disease
What this study did
NCT07523867 · Hospital de Messejana Dr. Carlos Alberto Studart Gomes
2026-04 – 2026-11 · Heart Failure, Diabetic Kidney Disease, Hyperkalemia
What this study did
NCT05887817 · Saga University
2023-09-07 – 2026-07-31 · Type 2 Diabetes, Chronic Kidney Diseases
What this study did
NCT06094920 · University Medical Center Groningen
2024-07-29 – 2025-09-24 · Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes, Diabetes Complications, Albuminuria, Chronic Kidney Diseases, Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, CKD, CKD Stage 3, CKD Stage 4
What this study did
Heart Failure
NCT07397650 · Juntendo University
2026-05-11 – 2028-09-30 · Acute Heart Failure
What this study did
NCT07830940 · Assiut University
2026-09-20 – 2028-03-25 · Heart Failure With Preserved Ejection Fraction
What this study did
NCT07583173 · China National Center for Cardiovascular Diseases
2026-05-15 – 2027-12-31 · Heart Failure
What this study did
NCT07351864 · Mansoura University
2026-01-18 – 2026-10-31 · Heart Failure
What this study did
Other / comorbidity
NCT07315191 · Capital Institute of Pediatrics, China
2025-06-13 – 2028-04-30 · Henoch Schönlein Purpura Nephritis
What this study did
NCT06573411 · First Affiliated Hospital, Sun Yat-Sen University
2024-09-30 – 2026-10-30 · Primary Membranous Nephropathy
What this study did
NCT06457074 · Chongqing Medical University
2024-06-04 – 2026-04-20 · Primary Aldosteronism
What this study did
NCT05814770 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-05 – 2026-03 · Primary Aldosteronism, Hypertension
What this study did
NCT06381323 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2024-03-01 – 2025-06-01 · Primary Aldosteronism, Finerenone, Mineralocorticoid Receptor Antagonist
What this study did
NCT06164379 · Shanghai Jiao Tong University School of Medicine
2023-12-16 – 2024-12-16 · Primary Aldosteronism
What this study did
NCT05924620 · Chongqing Medical University
2023-06-21 – 2024-03-12 · Primary Aldosteronism
What this study did
Early phase / not applicable (8)
Chronic Kidney Disease
NCT07585526 · Institute of Liver and Biliary Sciences, India
2026-04-15 – 2028-03-31 · MASLD, Chronic Kidney Diseases
What this study did
NCT07849348 · Peking University People's Hospital
2026-09 – 2027-02 · Obesity; Chronic Kidney Disease; Albuminuria
What this study did
NCT07326631 · College of Physicians and Surgeons Pakistan
2026-01-01 – 2026-07-01 · Diabetic Kidney Disease (DKD), Heart Failure
What this study did
NCT07056595 · Botkin Hospital
2025-05-21 – 2026-05-21 · IgA Nephropathy (IgAN)
What this study did
Other / comorbidity
NCT07775482 · Jean-Maxime Côté
2027-01 – 2030-01 · Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
What this study did
NCT07688928 · Bangladesh Medical University
2026-04-15 – 2027-09 · Primary Aldosteronism, Endocrine Hypertension
What this study did
NCT07678151 · Heart Health Research Center
2026-07-13 – 2027-08-31 · Hypertension (HTN)
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Chronic Kidney Disease
NCT05897372 · Iain Bressendorff
2023-08-01 – 2024-09-23 · Diabetic Kidney Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Heart Failure: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Finerenone (Kerendia): this drugApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Vericiguat (Verquvo)ApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Esaxerenone (Minnebro)
Phase 3(overall)
Small moleculeMineralocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 13 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(37 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Kerendia (Finerenone) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 4Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2026-11-30 · NCT06954090 · CT.gov ↗
What to watch
December 2026 (2)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2026-12-20 · NCT07235891 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT07026539 · CT.gov ↗
What to watch
2027 (18)
February 2027 (1)
Early phase / not applicableChronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-02 · NCT07849348 · CT.gov ↗
What to watch
March 2027 (2)
Early phase / not applicablePrimary Aldosteronism, Endocrine HypertensionRecruiting
Est. primary completion 2027-03 · NCT07688928 · CT.gov ↗
What to watch
Phase 2Kidney Transplant; ComplicationsRecruiting
Est. primary completion 2027-03-31 · NCT06059664 · CT.gov ↗
What to watch
April 2027 (3)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-04 · NCT07537088 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseActive not recruiting
Est. primary completion 2027-04-10 · NCT05196035 · CT.gov ↗
What to watch
Early phase / not applicableHypertension (HTN)Not yet recruiting
Est. primary completion 2027-04-30 · NCT07678151 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-05-01 · NCT07598864 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-07 · NCT07155694 · CT.gov ↗
What to watch
September 2027 (1)
Phase 4Heart FailureNot yet recruiting
Est. primary completion 2027-09-25 · NCT07830940 · CT.gov ↗
What to watch
October 2027 (4)
Phase 3Kidney Transplantation Recipients, Proteinuria PatientsActive not recruiting
Est. primary completion 2027-10-01 · NCT07356388 · CT.gov ↗
What to watch
Phase 4Henoch Schönlein Purpura NephritisRecruiting
Est. primary completion 2027-10-31 · NCT07315191 · CT.gov ↗
What to watch
Phase 4Heart FailureNot yet recruiting
Est. primary completion 2027-10-31 · NCT07583173 · CT.gov ↗
What to watch
Phase 4Chronic Kidney DiseaseNot yet recruiting
Est. primary completion 2027-10-31 · NCT07667517 · CT.gov ↗
What to watch
November 2027 (2)
Phase 3Heart FailureRecruiting
Est. primary completion 2027-11 · NCT06008197 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2027-11 · NCT06024746 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Premature Ovarian InsufficiencyNot yet recruiting
Est. primary completion 2027-12 · NCT07815509 · CT.gov ↗
What to watch
Phase 4Heart FailureRecruiting
Est. primary completion 2027-12 · NCT07397650 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2027-12-31 · NCT07181135 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic NeuropathiesRecruiting
Est. primary completion 2028-01 · NCT06906081 · CT.gov ↗
What to watch
March 2028 (1)
Early phase / not applicableChronic Kidney DiseaseNot yet recruiting
Est. primary completion 2028-03-31 · NCT07585526 · CT.gov ↗
What to watch
June 2028 (2)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-06 · NCT07239570 · CT.gov ↗
What to watch
Phase 2Atrial Fibrillation (AF)Recruiting
Est. primary completion 2028-06-30 · NCT07799519 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2028-08-07 · NCT05457283 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Heart FailureEnrolling by invitation
Est. primary completion 2028-12 · NCT07442448 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Early phase / not applicableAcute Kidney Injury, Renal Insufficiency,Chronic, Kidney DiseasesNot yet recruiting
Est. primary completion 2029-01 · NCT07775482 · CT.gov ↗
What to watch
February 2029 (1)
Phase 4Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-02-28 · NCT07775846 · CT.gov ↗
What to watch
March 2029 (1)
Phase 4Chronic Kidney DiseaseEnrolling by invitation
Est. primary completion 2029-03-31 · NCT07547878 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2029-07-01 · NCT06082063 · CT.gov ↗
What to watch
November 2029 (1)
Phase 3Heart FailureRecruiting
Est. primary completion 2029-11-30 · NCT07188805 · CT.gov ↗
What to watch
December 2029 (3)
Phase 2Heart FailureNot yet recruiting
Est. primary completion 2029-12-31 · NCT07594145 · CT.gov ↗
What to watch
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2029-12-31 · NCT06058585 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2029-12-31 · NCT07575672 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Phase 3Heart FailureNot yet recruiting
Est. primary completion 2030-12 · NCT07270367 · CT.gov ↗
What to watch
Phase 3Heart FailureRecruiting
Est. primary completion 2030-12-30 · NCT07192952 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 October 2026Filing acceptedFDA accepts Bayer's sNDA for finerenone (Kerendia) in adults with chronic kidney disease without diabetes (announced 2026-10-08)
US, FDA · Bayer · Source ↗
17 September 2026ApprovalFDA approves Kerendia for CKD associated with type 1 diabetes
US, FDA · Bayer · Source ↗
May 2026Priority reviewFDA grants Priority Review for finerenone in CKD with type 1 diabetes
US, FDA · Bayer · Source ↗
16 March 2026Topline resultFIND-CKD Phase III meets primary endpoint
March 2025Priority reviewFDA grants Priority Review for finerenone sNDA in heart failure
US, FDA · Source ↗